<DOC>
	<DOC>NCT01271517</DOC>
	<brief_summary>Hypothesis: Basal insulin analogs with continuous 24-hour delivery of insulin improve glycemic control during the first year of treatment of children/adolescents with type 1 diabetes mellitus (T1DM)by preserving endogenous insulin production and a close to normal balance of the GH-IGF-axis. This a randomized, open-label, parallel-group trial of 120 children, 7 - 17 years of age, newly diagnosed with T1DM. The investigators will investigate whether the use of long-acting basal insulin analogs Lantus (Glargine) or Levemir (Detemir) during the first year of treatment results in improved glycemic control (HbA1c) compared with Insulatard (NPH insulin) when given in a meal insulin therapy regimen with rapid acting Novorapid (insulin aspart). The investigators will explore possible mechanisms of action by determining remaining endogenous insulin production and changes in the GH-IGF-axis. The investigators will also assess changes in body composition and evaluate quality of life in each treatment arm.</brief_summary>
	<brief_title>Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Diagnosis of diabetes and novel to insulin therapy Age 7 17 years Informed consent Moderate to severe ketoacidosis (pH&lt;7.2 and/or standard bicarbonate &lt;10 mmol/l) Suspected nontype 1 IA2 and GAD65: allantibody negative Celiac disease or other chronic disease Hypothyroidism, if not well controlled Syndromes Previous anorexia nervosa Neuropsychiatric disease Malignancy</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Basal insulin</keyword>
	<keyword>long acting insulin analogs</keyword>
	<keyword>metabolic control</keyword>
	<keyword>HbA1c</keyword>
	<keyword>C-peptide</keyword>
	<keyword>IGF-I</keyword>
	<keyword>GH</keyword>
	<keyword>IGFBP</keyword>
</DOC>